Cardiac manifestations of GH deficiency after treatment for acromegaly: a comparison to patients with biochemical remission and controls.
نویسندگان
چکیده
OBJECTIVE Both GH excess and GH deficiency (GHD) lead to specific cardiac pathology. The aim of this study was to evaluate cardiac morphology and function in patients with GHD after treatment for acromegaly. DESIGN Cross-sectional study. PATIENTS AND METHODS Cardiac parameters were studied by conventional two-dimensional echocardiography and tissue Doppler imaging in 53 patients with acromegaly (16 patients with GHD, 20 patients with biochemical remission, and 17 patients with active disease). Patients with GHD were also compared with age- and gender-matched controls. RESULTS Left ventricular (LV) dimensions, wall thickness, and mass did not differ between the three groups, or between the patients with GHD and healthy controls. Systolic function, assessed by LV ejection fraction, tended to be lower in patients with GHD compared with patients with biochemical remission (65.9+/-7.3% vs 72.4+/-8.5%, P=0.070), but was higher when compared with active acromegaly (58.8+/-9.3%, P=0.047). No differences were found with healthy controls. Diastolic function, measured with early diastolic velocity (E'), was lower in patients with GHD when compared with both patients with biochemical remission (6.0+/-2.1 cm/s vs 8.3+/-1.5 cm/s, P=0.005) and healthy controls (8.1+/-1.9 cm/s, P=0.006). CONCLUSION GHD after acromegaly results in a specific decrease in diastolic function compared with patients with biochemical remission of acromegaly and healthy controls. In addition, systolic function tends to be decreased in patients with GHD compared with patients with biochemical remission, but was higher than that in patients with active acromegaly.
منابع مشابه
The Combination Therapy with Bromocriptine and Cyproheptadine in Patients with Acromegaly
The therapeutic efficacy of the combination of cyproheptadine and bromocriptine was studied in 15 patients with active acromegaly showing incomplete GH suppression in response to bromocriptine therapy alone. The mean basal plasma GH was 31.3±5.5 µg/L, and it decreased to 19.0±3.9 µg/L during the single bromocriptine therapy (10-20 mg for 2 to 21 months). When cyproheptadine (12 to 16 mg for 8 t...
متن کاملEffects of Low-Dose Recombinant Human Growth Hormone on Bone Densities of Radius, Tibia and 4th Lumbar Vertebrae in Rabbits
Objective- To determine the effects of growth hormone (GH) therapy on bone density in controlled conditions in healthy adult rabbits. Design- Experimental in vivo study. Animal- 20 healthy, adult New Zealand White rabbits. Procedures- The rabbits were divided into 2 groups; receiving Human GH (0.006 mg/kg/d) and controls; receiving placebo for 3 months. The density of radius and tibia was m...
متن کاملActive postoperative acromegaly: sustained remission after discontinuation of somatostatin analogues
In patients with active acromegaly after pituitary surgery, somatostatin analogues are effective in controlling the disease and can even be curative in some cases. After treatment discontinuation, the likelihood of disease recurrence is high. However, a small subset of patients remains symptom-free after discontinuation, with normalized growth hormone (GH) and insulin-like growth factor (IGF1) ...
متن کاملConventional pituitary irradiation is effective in normalising plasma IGF-I in patients with acromegaly.
OBJECTIVE For patients in whom acromegaly persists despite pituitary surgery, conventional pituitary irradiation represents an additional treatment option. A 30-60% cure rate is described in the literature, but these studies did not utilise strict rules of remission, such as "safe" GH levels <2.5 microg/l, and age-adjusted normal IGF-I levels. DESIGN AND METHODS We report the outcome of 41 pa...
متن کاملPreliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal.
OBJECTIVE It is still unknown whether prolonged treatment with somatostatin analogs (SSTa) may cause a long-lasting disease remission in GH-secreting adenomas after drug discontinuation. The aim of the present study was to investigate the evolution of GH/IGF-I secretion and tumor mass after SSTa withdrawal in patients affected by acromegaly. PATIENTS AND DESIGN A total of 27 patients with acr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- European journal of endocrinology
دوره 159 6 شماره
صفحات -
تاریخ انتشار 2008